Abstract
In this study, we assessed the adverse effects and the work and daily life interference associated with each dose of the ChAdOx1 and BNT162b2 COVID-19 vaccines. Questionnaires were distributed to workers after they received both doses; only those who worked the day after receiving the vaccine were included in the analysis. Overall, 368 ChAdOx1-vaccinated and 27 BNT162b2-vaccinated participants were included. Among the ChAdOx1-vaccinated participants, the incidence of adverse effects was significantly lower after the second dose than after the first dose. Among the BNT162b2-vaccinated participants, however, no differences in adverse effects or work and daily life interference were found between the doses. After the first and second dose, the numeric scale score (0–10) for interference with work was 3.9 ± 2.9 and 1.6 ± 1.9 for the ChAdOx1 and 3.2 ± 2.5 and 3.6 ± 3.0 for the BNT162b2 vaccine, respectively. A similar trend was observed for interference with daily life. Factors associated with work and daily life interference in the multivariate model were age, vaccine dose (first or second), and the interaction term of vaccine type and dose. These results could be used to inform the general population of the adverse effects associated with these vaccinations.
Highlights
As of 15 June 2021, over 15 million COVID-19 vaccination doses have been administered in the Republic of Korea [1], which represents approximately 30% of the population.With the increase in vaccination rates, many cases of adverse effects have been reported, including those that are common and less severe [2,3] and those that are more rare, but critical [4,5]
Since a primary objective of this study was to assess the association between the vaccine and interference with work, those who did not work on the day after receiving the vaccine for both doses were excluded from the analysis
A survey was conducted, which focused on the adverse effects and interference with daily life and work experienced by workers at our institution the day after receiving the first and second doses of the ChAdOx1 and BNT162b2 vaccinations
Summary
As of 15 June 2021, over 15 million COVID-19 vaccination doses have been administered in the Republic of Korea [1], which represents approximately 30% of the population.With the increase in vaccination rates, many cases of adverse effects have been reported, including those that are common and less severe [2,3] and those that are more rare, but critical [4,5]. The reported rates of adverse effects have been inconsistent [6,7] because of differences in age, ethnicity, and underlying diseases. We utilized a numeric scale (0–10) to determine the severity of the adverse effects and the extent to which they interfered with work and daily life This numeric scale is widely used to assess the influence of a group of certain types of diseases on daily life [10,11,12] and can be understood intuitively
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
